Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

bioAffinity Technologies (BIAF) Long-Term Debt Issuances (2021 - 2022)

bioAffinity Technologies has reported Long-Term Debt Issuances over the past 1 years, most recently at $249000.0 for Q3 2022.

Quarterly Long-Term Debt Issuances changed N/A to $249000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $724000.0 through Dec 2022, changed N/A year-over-year, with the annual reading at $724000.0 for FY2022, 241.09% up from the prior year.
Long-Term Debt Issuances was $249000.0 for Q3 2022 at bioAffinity Technologies, down from $475000.0 in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $475000.0 in Q1 2022 and troughed at $249000.0 in Q3 2022.